March 4, 2024
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating new side effect risks for four CAR-T cell therapy products including Gilead Sciences’ Yescarta (axicabtagene ciloleucel), a move expected to lead to label changes in the near future. According to a...read more